Skip to main content
 
Navbar Image
 
This site is intended only for US healthcare professionals.

 

Trilaciclib is a recommended option for patients with ES-SCLC in both NCCN Guidelines® and ASCO® clinical guidelines

NCCN Guidelines

  • NCCN Category 2A: Recommended as a prophylactic option to reduce chemotherapy-induced myelosuppression in ES-SCLC3,4,a-c
  • NCCN Category 2B: Recommended as a prophylactic option for decreasing anemia and the need for red blood cell transfusions in ES-SCLC3,b,d

ASCO Guidelines

  • COSELA may be used if clinically indicated in patients with ES-SCLC5
ASCO=American Society of Clinical Oncology; ES-SCLC=extensive-stage small cell lung cancer; G-CSF=granulocyte colony-stlmulatlng factor; NCCN=National Comprehensive Cancer Network.
a
Trilaciclib may be used as a prophylactic option to decrease the incidence of chemotherapy-induced myelosuppression when administered before (prophylactic G-CSF may be administered after cycle 1) platinum/etoposide ± immune checkpoint inhibitor-containing regimens or a topotecan-containing regimen for ES-SCLC. Use of trilaciclib in this setting is a category 2A recommendation (based upon lower-level evidence, there is uniform NCCN consensus (>85% support of the panel) that the intervention is appropriate).
b
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hematopoietic Growth Factors V.3.2026. © National Comprehensive Cancer Network, Inc. 2025 All rights reserved. Accessed November 18, 2025. To view the most recent and complete version of the guidelines, visit NCCN.org.
c
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Small Cell Lung Cancer V.2.2026. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed October 14, 2025. To view the most recent and complete version of the guidelines, visit NCCN.org.
d
Trilaciclib may be used as a prophylactic option to decrease the incidence of anemia and red blood cell (RBC) transfusions when administered before platinum/etoposide ± immune checkpoint inhibitor-containing regimens or a topotecan-containing regimen for ES-SCLC. Use of trilaciclib in this setting is a category 2B recommendation (based upon lower-level evidence, there is uniform NCCN consensus (>50%, but <85% support of the panel) that the intervention is appropriate).

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

ASCO makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.